X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare SUVEN LIFE with PLETHICO PHARMA - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SUVEN LIFE vs PLETHICO PHARMA - Comparison Results

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SUVEN LIFE PLETHICO PHARMA SUVEN LIFE/
PLETHICO PHARMA
 
P/E (TTM) x 19.2 -1.1 - View Chart
P/BV x 3.6 0.0 21,201.2% View Chart
Dividend Yield % 1.1 0.0 -  

Financials

 SUVEN LIFE   PLETHICO PHARMA
EQUITY SHARE DATA
    SUVEN LIFE
Mar-16
PLETHICO PHARMA
Mar-14
SUVEN LIFE/
PLETHICO PHARMA
5-Yr Chart
Click to enlarge
High Rs339395 85.7%   
Low Rs14431 461.3%   
Sales per share (Unadj.) Rs39.2604.4 6.5%  
Earnings per share (Unadj.) Rs7.532.5 23.0%  
Cash flow per share (Unadj.) Rs8.851.3 17.1%  
Dividends per share (Unadj.) Rs2.000-  
Dividend yield (eoy) %0.80-  
Book value per share (Unadj.) Rs49.0473.6 10.3%  
Shares outstanding (eoy) m127.2834.08 373.5%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x6.20.4 1,744.9%   
Avg P/E ratio x32.46.6 493.2%  
P/CF ratio (eoy) x27.54.2 662.7%  
Price / Book Value ratio x4.90.5 1,095.1%  
Dividend payout %26.80-   
Avg Mkt Cap Rs m30,7327,262 423.2%   
No. of employees `0001.0NA-   
Total wages/salary Rs m4161,596 26.1%   
Avg. sales/employee Rs Th5,236.1NM-  
Avg. wages/employee Rs Th436.5NM-  
Avg. net profit/employee Rs Th995.5NM-  
INCOME DATA
Net Sales Rs m4,99520,598 24.3%  
Other income Rs m194386 50.1%   
Total revenues Rs m5,18920,984 24.7%   
Gross profit Rs m1,2332,818 43.7%  
Depreciation Rs m167642 26.0%   
Interest Rs m541,593 3.4%   
Profit before tax Rs m1,205969 124.4%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m255-138 -184.3%   
Profit after tax Rs m9501,107 85.8%  
Gross profit margin %24.713.7 180.4%  
Effective tax rate %21.2-14.3 -148.1%   
Net profit margin %19.05.4 353.8%  
BALANCE SHEET DATA
Current assets Rs m4,98618,877 26.4%   
Current liabilities Rs m1,04211,896 8.8%   
Net working cap to sales %79.033.9 233.0%  
Current ratio x4.81.6 301.5%  
Inventory Days Days6136 169.7%  
Debtors Days Days39198 19.8%  
Net fixed assets Rs m3,1269,861 31.7%   
Share capital Rs m127341 37.4%   
"Free" reserves Rs m3,71712,331 30.1%   
Net worth Rs m6,23616,139 38.6%   
Long term debt Rs m4324,706 9.2%   
Total assets Rs m8,07933,146 24.4%  
Interest coverage x23.21.6 1,444.6%   
Debt to equity ratio x0.10.3 23.8%  
Sales to assets ratio x0.60.6 99.5%   
Return on assets %12.48.1 152.5%  
Return on equity %15.26.9 222.0%  
Return on capital %18.912.3 153.6%  
Exports to sales %87.521.4 409.4%   
Imports to sales %12.215.2 80.3%   
Exports (fob) Rs m4,3714,402 99.3%   
Imports (cif) Rs m6113,136 19.5%   
Fx inflow Rs m4,6664,402 106.0%   
Fx outflow Rs m9423,184 29.6%   
Net fx Rs m3,7241,219 305.7%   
CASH FLOW
From Operations Rs m9222,437 37.8%  
From Investments Rs m-619-6,265 9.9%  
From Financial Activity Rs m-6982,490 -28.0%  
Net Cashflow Rs m-396-1,337 29.6%  

Share Holding

Indian Promoters % 63.4 82.7 76.7%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.0 4.3 -  
FIIs % 0.0 5.5 -  
ADR/GDR % 0.0 0.0 -  
Free float % 36.5 7.5 486.7%  
Shareholders   37,287 10,665 349.6%  
Pledged promoter(s) holding % 0.0 85.7 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SUVEN LIFE With:   TORRENT PHARMA  NATCO PHARMA  AJANTA PHARMA  PFIZER  ALKEM LABORATORIES  

Compare SUVEN LIFE With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Strong Finish to the Week; Metal & Pharma Stocks Gain(Closing)

Indian share markets finished the trading session on a strong note amid firm Asian markets after comments from a Federal Reserve official eased worries about faster rate hikes in US.

Related Views on News

Suven Lifesciences: Profits Decline due to Higher tax outgo in the quarter (Quarterly Results Update - Detailed)

Sep 22, 2017

Muted growth in CRAMS segment continues to impact topline.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

India's Rs 1,66,276 Crore Problem(Vivek Kaul's Diary)

Feb 15, 2018

That's the loss, the government owned public sector enterprises are expected to make this year.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

How I Beat the Index by 2x... And Why I Believe This Could Happen Again(Smart Contrarian)

Feb 12, 2018

Will Microcap Millionaires be able to replicate its past performance of beating the index by 2x?

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

SUVEN LIFE SHARE PRICE


Feb 23, 2018 (Close)

TRACK SUVEN LIFE

  • Track your investment in SUVEN LIFE with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

COMPARE SUVEN LIFE WITH

MARKET STATS